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Background: Inhibition of metastasis through upregulation of immune surveillance is a major purpose of chemokine
gene therapy. In this study, we focused on a membrane-bound chemokine CXCL16, which has shown a correlation
with a good prognosis for colorectal cancer (CRC) patients.
Methods: We generated a CXCL16-expressing metastatic CRC cell line and identified changes in TNF and apoptosis-
related factors. To investigate the effect of CXCL16 on colorectal liver metastasis, we injected SL4-Cont and SL4-CXCL16
cells into intraportal vein in C57BL/6 mice and evaluated the metastasis. Moreover, we analyzed metastatic liver tissues
using flow cytometry whether CXCL16 expression regulates the infiltration of M1 macrophages.
Results: CXCL16 expression enhanced TNF-α-induced apoptosis through activation of PARP and the caspase-3-
mediated apoptotic pathway and through inactivation of the NF-κB-mediated survival pathway. Several genes
were changed by CXCL16 expression, but we focused on IRF8, which is a regulator of apoptosis and the metastatic
phenotype. We confirmed CXCL16 expression in SL4-CXCL16 cells and the correlation between CXCL16 and IRF8.
Silencing of IRF8 significantly decreased TNF-α-induced apoptosis. Liver metastasis of SL4-CXCL16 cells was also
inhibited by TNF-α-induced apoptosis through the induction of M1 macrophages, which released TNF-α. Our findings
suggest that the accumulation of M1 macrophages and the enhancement of apoptosis by CXCL16 might be an
effective dual approach against CRC liver metastasis.
Conclusions: Collectively, this study revealed that CXCL16 regulates immune surveillance and cell signaling.
Therefore, we provide the first evidence of CXCL16 serving as an intracellular signaling molecule.
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Colorectal cancer (CRC) is the most commonly diagnosed
cancer worldwide [1]. Metastasis is the major cause of
CRC mortality, and surgery is the only feasible therapy
with very low mortality. However, only 10-20% of CRC
patients with liver metastasis are candidates for surgery [2].
Consequently, gene therapy is viewed as a promising treat-
ment strategy that can complement the use of existing* Correspondence: kkoizumi@inm.u-toyama.ac.jp
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in these patients [3].
Chemokines are a family of small cytokines that func-
tion as chemoattractants for several immune effector cell
types [4]. Recent studies demonstrated that various che-
mokines have the potential to suppress tumor growth and
metastasis [4,5]. One unique membrane-bound chemo-
kine is chemokine (C-X-C motif ) ligand 16 (CXCL16),
which exists as a transmembrane form (TM-CXCL16)
as well as a soluble form (sCXCL16) that is cleaved by
proteolytic enzymes [6-11]. TM-CXCL16 can function
as a cell adhesion molecule for its receptor cells that
express CXCR6, such as activated CD8 T cells andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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a chemoattractant for CXCR6-expressing cells [12,13].
Recently, the chemokine/receptor axis has been shown
to play a critical role in tumor progression and metas-
tasis [14]. With respect to the CXCL16/CXCR6 axis,
we were the first to report that CXCL16 expression by
tumor cells enhances the recruitment of tumor-infiltrating
lymphocytes, thereby bringing about a better prognosis
for CRC patients [15]. Our studies have confirmed the ex-
pression of CXCL16 in various cancer cell lines and tumor
tissues [16-23], indicating that CXCL16 might serve as a
useful biomarker for various types of cancer.
Macrophages function in both innate and adaptive
immunity as immune regulatory cells. In particular, tumor-
associated macrophages (TAMs) play an important role in
the progression and metastasis of cancer [24]. TAMs have
been typically defined as M1- and M2-type macrophages.
M1 macrophages are potent effector cells that induce Th1
responses such as cytotoxicity against microorganisms and
cancer cells and enhancement of pro-inflammatory cyto-
kine production [25,26]. Tumor-infiltrating macrophages
are reported to reduce the development of peritoneal colo-
rectal carcinoma metastasis [27], while liver macrophages
exert a protective function against cancer cells and inhibit
liver metastasis due to their cytotoxic action against cancer
cells through the production of tumor necrosis factor-
alpha (TNF-α) [28-30].
TNF-α is typically produced by macrophages that show
antitumor activity [31]. TNF-α stimulates intracellular
signaling pathways involving caspases, mitogen-activated
protein kinases (MAPKs), and nuclear factor kappa B
(NF-κB). Activation of the caspases involved in apoptosis
results in the cleavage of a large number of nuclear
proteins that are essential for apoptosis-associated
chromatin margination, DNA fragmentation, and nuclear
collapse [32].
Interferon regulatory factor 8 (IRF8) is expressed in cells
of myeloid and lymphoid lineages and serves as a key tran-
scription factor [33,34]. IRF8 has been shown to regulate
Fas-mediated apoptosis in myeloid cells and soft tissue
sarcoma cells [35,36]. Deficiency of IRF8 in metastatic hu-
man CRC cells leads to decreased spontaneous apoptosis
and enhanced resistance to the induction of extrinsic
apoptosis [37,38]. IRF8 is also an essential regulator of the
apoptosis pathway and a suppressor of metastasis [39].
In a previous study, we identified genes which expression
was changed by CXCL16 expression in metastatic CRC
cells. Among these genes, the expression of IRF8 was cor-
related with CXCL16 expression and showed sensitivity to
TNF-α-induced apoptosis. In addition, CXCL16 expression
induced the infiltration of M1 macrophages into metastatic
tumors and inhibited liver metastasis by releasing TNF-α,
thereby inducing the apoptosis of CXCL16-expressing
metastatic CRC cells.Methods
Antibodies and reagents
Anti-phospho p65 (Ser-536), Akt (Ser-473), JNK (Thr183/
Tyr185), ERK (Thr-202, Tyr-204), p38 (Thr-180/Tyr-182),
PARP (46D11) and caspase-3 (8G10) antibodies were
purchased from Cell Signaling Technology (Danvers, MA,
USA). Antibodies against Akt (C-20), p38 (C-20), JNK
(FL), ERK1 (C-16), p65 (C-20-G), IκBα (L35A5), IRF8
(C-19) and β-actin (C-11) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). CXCL16
antibody and recombinant mouse TNF-α were obtained
from R&D Systems (Minneapolis, MN, USA). Mouse TNF-
α neutralizing antibody and 2-chloroadenosine were pur-
chased from eBioscience (San Diego, CA, USA) and Sigma
(St Louis, MO, USA), respectively.
Cell culture
The mouse colon carcinoma cell lines, colon 38 and
colon 38 SL4 (SL4), were maintained in a 1:1 mixture of
Dulbecco’s modified Eagle’s medium and Ham’s F-12
medium (DMEM/F12; Invitrogen, Carlsbad, CA, USA).
The mouse leukemic monocyte macrophage cell line,
RAW 264.7, was maintained in DMEM. The media con-
tained 10% heat-inactivated fetal calf serum (FCS), 100
units/ml penicillin, and 100 μg/ml streptomycin.
Generation of CXCL16-expressing CRC cell line
We generated pcDNA3.1 (+)-CXCL16, which was based
on the pcDNA 3.1 (+) expression vector (Life Technologies
Japan Ltd., Tokyo, Japan), to express the mouse membrane-
bound CXCL16. Nucleofector (Amaxa, Gaithersburg,
MD, USA) was used to transfect colon 38 SL4 cells with
pcDNA3.1 (+)-CXCL16 or the empty vector. DNA was
adjusted to 1 μg with the empty vector. After transfection,
CXCL16-positive colon 38 SL4 cells were selected using
the antibiotic G418 (Invitrogen). Cells stably expressing
CXCL16 (SL4-CXCL16) and control cells (SL4-Cont) were
maintained in DMEM/F12 supplemented with 10% FCS
and antibiotics.
WST-8 assay
Cell viability was quantified using the cell prolifera-
tion reagent WST-8 (2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium, mo-
nosodium salt) (Dojindo, Kumamoto, Japan). Cells were
seeded in 96-well microplates (2 × 103 cells) and then
TNF-α was added. After 24-48 h incubation, WST-8 so-
lution was added and the absorbance was measured at
450 nm.
Microarray analysis
Gene expression was analyzed using a GeneChip1 sys-
tem with the mouse Expression Array 430.2 (Affymetrix,
Santa Clara, CA, USA). Samples were prepared for array
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In brief, 2 μg total RNA was used to synthesize double-
stranded cDNA with a GeneChip1 Expression 30-
Amplification Reagents One-Cycle cDNA Synthesis
Kit (Affymetrix). Subsequently, biotin-labeled cRNA was
synthesized from cDNA using the GeneChip1 Expression
30-Amplification Reagents for IVT Labeling (Affymetrix).
Following fragmentation, biotinylated cRNA was hybrid-
ized to arrays at 45°C for 16 h. The arrays were washed,
stained with streptavidin–phycoerythrin, and scanned with
a probe array scanner. The scanned chip was analyzed
using GeneChip Microarray Suite software (Affymetrix).
Hybridization intensity data were converted into a
presence/absence call for each gene, and changes in
gene expression between experiments were detected via
comparison analysis. Data were further analyzed using
GeneSpring (Silicon Genetics, Redwood City, CA, USA).
The GeneSpring Filter on the Volcano Plot tool was im-
plemented to obtain a list of differentially expressed sig-
nificant genes. A fold change value greater (upregulated)
or less than 2 (downregulated) was considered biologically
important. The statistical significance of the fold change
was calculated for 2 groups by Student’s t-test and P
values less than 0.05 were considered significant.
Reverse-transcription PCR (RT-PCR)
Total RNA was extracted using an RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s directions. First-strand cDNA was prepared from
an RNA template (2 μg) using oligo (dT) 18 primer and
SuperScript III reverse transcriptase (Invitrogen). Reverse
transcription was performed at 42°C for 50 min and
then at 70°C for 15 min. PCR amplification was per-
formed by denaturation at 94°C for 5 s, annealing at 60°C
for 5 s, and extension at 72°C for 10 s for 28 cycles using a
SappireAmp Fast PCR Master Mix (TaKaRa, Kyoto,
Japan). Forward/reverse RT-PCR primer pairs for mouse
cDNAs were as follows: CD11b (5′-ACACCATCGCATC
TAAGCCA-3′/5′-GAACATCACCACCAAGCCAA-3′);Figure 1 Establishment of a cell line that stably overexpressed CXCL1
and SL4-CXCL16 cells were cultured for 24 h and lysed to extract total RNA
SL4-Cont levels, which were assigned a value of 1. (B) Protein level of CX






TGGGCCATGAGGTCCACCAC-3′). PCR products were
electrophoresed on 1.5% agarose gels and stained with
SYBR green. Images were acquired by Gel Doc EZ Imager
(Bio-Rad, Hercules, CA, USA).
Real-time RT-PCR (qRT-PCR)
The cDNAs were amplified using FastStart Essential DNA
Green Master (Roche, Pleasanton, CA, USA). Forward/













RT-PCR (qRT-PCR) was performed using a Lightcycler
nano system (Roche). The gene expression data were
normalized to the β-actin. The relative expression levels
of genes were measured according to the formula 2-ΔCt,
where ΔCt is the difference in threshold cycle values
between the targets and β-actin.
Transfection with small interfering RNA (siRNA)
Mouse IRF8 siRNA and control siRNA were pur-
chased from Santa Cruz Biotechnology. Mouse CXCL16
siRNA was purchased from Ambion Life Technologies
(Carlsbad, CA, USA). SL4 cells were transfected with6. (A) The mRNA level of CXCL16 was analyzed by qRT-PCR. SL4-Cont
. These data were normalized to GAPDH and expressed relative to the
CL16. Cells were seeded in a 24-well plate and the supernatant was
peated at least three times.






Irf8 11.89 Interferon regulatory factor 8
Ccnd1 0.45 Cyclin D1
Casp8 0.39 Caspase 8
Bag4 0.33 Bcl2-associated athanogene 4
Bcl2l10 0.33 Bcl2-like 10
Casp9 0.33 Caspase 9
Mapk1 0.33 Mitogen-activated protein kinase
1
Bcl2l2 0.11 BCL2-like 2
TNF-related factors
Ltbr 16.90 Lymphotoxin B receptor
Tnfrsf22 5.83 Tumor necrosis factor receptor
superfamily, member 22
Traf4 4.10 TNF receptor associated factor 4
MAP3K7 2.13 Mitogen-activated protein kinase
kinase kinase 7
Ttrap 2.01 TRAF and TNF receptor associated
protein
Irak1 7.84 Interleukin-1 receptor-associated
kinase 1
Traf6 0.44 TNF receptor associated factor 6
Tnfaip2 0.41 Tumor necrosis factor, alpha-
induced protein 2
IRAK4 0.36 Interleukin-1 receptor-associated
kinase 4
Tnfrsf11a 0.15 Tumor necrosis factor receptor
superfamily, member 11a
Others
Tnni2 49.02 Troponin I, skeletal, fast 2
Myh3 34.13 Myosin, heavy polypeptide 3,
skeletal muscle embryonic
Pi16 23.76 Peptidase inhibitor 16
Tnni1 20.89 Troponin I, skeletal, slow 1
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nM (si-CXCL16) using Lipofectamine reagents (Invitrogen).
After 5 h, the medium was changed to normal medium
and cells were cultured for a further 24 h.
Annexin V assay
The Annexin V assay was carried out using Annexin V
Apoptosis Detection Kit I (BD Biosciences, San Diego,
CA, USA). In brief, harvested cells (1 × 106 cells) were
washed twice with phosphate-buffered saline (PBS) and
cells were resuspended in 1 ml Annexin V binding buffer.
Then, 100 μl of the solution was transferred to a 5 ml cul-
ture tube and labeled with 2 μl titrated FITC Annexin V
and Propidium Iodide Staining Solution (PI). The cells
were vortexed and incubated for 15 min at room tem-
perature in the dark. The volume was then made up to
500 μl and the cells were analyzed with the FACSCalibur
system (BD Biosciences).
Western blot analysis
Cells were harvested, plated on a 6 cm dish (1 × 106 cells)
and stimulated with TNF-α (10 ng/ml). Whole-cell lysates
were prepared with lysis buffer (25 mM HEPES pH 7.7,
0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 10% Triton
X-100, 20 mM β-glycerophosphate, 1 mM sodium ortho-
vanadate, 1 mM dithiothreitol (DTT), 10 μg/ml aproti-
nin, and 10 μg/ml leupeptin). Cell lysates were collected
from the supernatant after centrifugation for sulfate-
polyacrylamide gel electrophoresis and transferred to
an immobilon-P-nylon membrane (Millipore, Bedford,
MA, USA). The membrane was blocked with Block Ace
(Dainippon Pharmaceutical, Osaka, Japan) and probed
with primary antibodies. The antibodies were detected
using horseradish peroxidase-conjugated anti-rabbit and
anti-mouse immunoglobulin G (Dako, Glostrup, Denmark)
and blots were detected using the ECL system (GE Health-
care, Piscataway, NJ, USA).
Experimental liver metastasis
For experimental liver metastasis, colon 38 SL4 cells
(7.5 × 104 cells/200 μl PBS) were injected into the intra-
portal vein of mice. The animals were sacrificed 17 days
later and the increases in liver weight and the numbers
of tumor colonies in the livers were measured to evalu-
ate tumor metastasis. All experimental protocols were
approved by the Laboratory Animal Care and Use Com-
mittee of Toyama University and were performed accord-
ing to the Guidelines for the Care and Use of Laboratory
Animals of Toyama University. Five-week-old female
C57BL/6 mice (supplied by Japan SLC, Inc., Hamamatsu,
Japan) were used in all experiments. Room temperature
was maintained between 23 and 25°C, and relative humidity
was maintained between 45 and 60%. The institutional
laboratory housing the cages provided a 12-hour light cycle.Statistical analysis
Data were analyzed for statistical significance using Stu-
dent’s t-test. P < 0.05 was considered significant. The mean
and SD were calculated for all variables.
Results
CXCL16 expression enhances the sensitivity of metastatic
CRC cells to TNF-α-induced apoptosis
We established a stable expression of CXCL16 in SL4,
a metastatic mouse CRC cell line, and confirmed its
expression (Figure 1). This cell line was cultured in a
polyclonal population with a different expression level
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erozygous characteristics of cancer cells. Membrane-
bound CXCL16 was confirmed in almost SL4-CXCL16
cells by flow cytometry (Additional file 1). We next
performed microarray analysis to compare gene expres-
sions between SL4-Cont and SL4-CXCL16 cells. Signi-
ficant differences were noted in the expression of TNF
and apoptosis-related factors, whereas no changes wereFigure 2 CXCL16 overexpression sensitizes SL4 cells to TNF-α-induced
TNF-α stimulation. Cells were seeded in 96-well plates (2 × 103 cells) stabiliz
**P <0.01. (B) Annexin V assay. Cells were seeded in 6-well plates (2 × 105 c
expression on the TNF-α-induced apoptotic pathway in SL4 cells. (D) Effects o
pathways in SL4 cells. β-actin was used as a normalization control. All experimobserved in metastatic factors (Table 1). On the other
hand, soluble CXCL16 did not affect SL4-CXCL16 cells
via the paracrine system because expression of CXCR6
(CXCL16 receptor) was not observed on SL4-CXCL16
cells (Additional file 2). When SL4-Cont and SL4-
CXCL16 cells were treated with TNF-α, this induced a
time-dependent increase in the death of SL4-CXCL16
cells (Figure 2A). We carried out the Annexin V assaycell death. (A) Viability of SL4-Cont and SL4-CXCL16 cells following
ed for 1 h and stimulated by TNF-α (10 ng/ml) for 24–48 h. *P <0.05,
ells) and treated with TNF-α (10 ng/ml) for 0-8 h. (C) Effects of CXCL16
f CXCL16 expression on the TNF-α-induced NF-κB and MAPK signaling
ents were repeated at least three times.
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apoptosis. As shown in Figure 2B, apoptosis was greater in
TNF-α-treated SL4-CXCL16 cells than in SL4-Cont cells.
The TNF-α-induced apoptotic response involved the
stimulation of several intercellular signaling pathways
[32]. Western blot analysis revealed an increase in the
cleavage of PARP and caspase-3 in SL4-CXCL16 cells
(Figure 2C). In addition, TNF-α-induced activation of
TAK1 and its downstream NF-κB decreased, whereas phos-
phorylation of ERK and JNK increased in SL4-CXCL16
cells (Figure 2D). These results suggested that CXCL16 ex-
pression sensitized metastatic CRC cells to TNF-α-induced
apoptosis.Figure 3 Correlation of CXCL16 and IRF8 expression in SL4 cells. (A) E
and analyzed by qRT-PCR. These data were normalized to GAPDH. (B) Knoc
siRNA for 36 h to assess the expression of CXCL16 at the mRNA (upper pan
SL4-CXCL16 using siRNA for control and CXCL16. β-actin was used as a no
at least three times.Expression of CXCL16 correlates with IRF8 expression in
metastatic CRC cells
IRF8 has been shown to be a key regulator of Fas-mediated
apoptosis in various cancer cells [34-36] and metastatic
phenotypes in CRC cells [37,38]; however, the correlation
between TNF-α-induced apoptosis and IRF8 expression
in CRC cells has not been investigated. We confirmed
that IRF8 expression was increased in SL4-CXCL16 cells
(Figure 3A). In contrast, IRF8 expression was significantly
decreased by CXCL16 knockdown (Figure 3C), although
CXCL16 expression was not completely silenced by siRNA
(Figure 3B). These results indicated that the expression of
IRF8 correlates with CXCL16 expression.xpression of IRF8 in SL4-Cont and SL4-CXCL16 cells cultured for 24 h
kdown of CXCL16 expression. SL4-CXCL16 cells were transfected with
el) and protein (lower panel) levels. (C) Expression levels of IRF8 in
rmalization control. *P <0.05, **P <0.01. All experiments were repeated
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induced apoptosis
The increased sensitivity to TNF-α-induced apoptosis
and IRF8 expression apparent in SL4-CXCL16 cells led
us to hypothesize that IRF8 expression was related to sen-
sitivity to TNF-α-induced apoptosis. Regulation of TNF-
α-induced apoptosis by IRF8 has not been previously
reported, even though it regulates Fas-mediated apoptosis
[34-38]. When SL4-CXCL16 cells were transfected with
IRF8 siRNA (Figure 4A) and stimulated with TNF-α,
TNF-α-induced apoptosis was significantly inhibited in
IRF8 knockdown cells compared with control siRNA-
transfected cells (si-Cont) (Figure 4B and C). The in-
creased activation of caspase-3 and PARP observed inFigure 4 Silencing of IRF8 expression by siRNA inhibited TNF-α-induc
qRT-PCR and Western blot analysis. (B) Viability of IRF8 knockdown cells sti
and stimulated with TNF-α (10 ng/ml) for 0–72 h and then viability was me
seeded in 6-well plates (2 × 105 cells) and treated with TNF-α (10 ng/ml). (D
si-Control; I, si-IRF8. All experiments were repeated at least three times.SL4-CXCL16 cells was also decreased in IRF8 knock-
down cells (Figure 4D). These results suggested that
CXCL16-mediated upregulation of TNF-α-induced apop-
tosis in IRF8-sensitized SL4-CXCL16 cells occurred via
downstream caspase-3 and PARP signaling.
Tumor-derived CXCL16 expression inhibited liver
metastasis
The liver is a major metastatic organ of CRC and no
specific therapeutic method is available for liver metas-
tasis other than surgical resection [2]. Our finding that
CXCL16 expression enhanced the sensitivity of SL4-
CXCL16 to TNF-α led us to hypothesize that enhanced
sensitivity to TNF-α by CXCL16 expression inhibits in vivoed apoptosis in SL4-CXCL16. (A) Knockdown of IRF8 expression by
mulated with TNF-α. Cells were seeded in 96-well plates (2 × 103 cells)
asured by the WST-8 assay. *P <0.05. (C) Annexin V assay. Cells were
) Effects of IRF8 knockdown on TNF-α-induced apoptotic responses. C,
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injection of cells into C57BL/6 mice significantly inhibited
liver metastasis in the SL4-CXCL16 group compared with
the SL4-Cont group (Figure 5B). The difference in tumor
weight was evaluated after dividing the resected liver into
normal and tumor parts. Tumor weight was significantly
lower in the SL4-CXCL16 group than in the SL4-Cont
group (Figure 5C).
Macrophages mediated the inhibition of liver metastasis
by CXCL16 through secretion of TNF-α
CXCL16 has been reported to play an important role in
immunosurveillance as a chemoattractant [12,13]. We
determined the mechanism of the inhibition of liver me-
tastasis by CXCL16 by carrying out RT-PCR to identify
the types of cells that infiltrated the liver. As shown in
Figure 6A, the levels of M1 macrophage markers such as
CD11b, CD11c and F4/80 were increased at the tumor
sites. We hypothesized that M1 macrophages were re-
cruited and inhibited liver metastasis through the secre-
tion of TNF-α. The M1 phenotype is typically IL-12, TNF-α,
IL-6, CXCL9, CXCL10, CXCL11, CXCL16, IL-8high, whereas
the M2 phenotype is IL-10, CXCR1, CXCR2, CCL17,
CCL22, CCL24, CCL16, CCL18, CCL1, CCR2high [26].Figure 5 Tumor-derived CXCL16 inhibited liver metastasis by metasta
on liver metastasis. Horizontal bar is the mean of the data points/group. (C
three independent experiments (n = 8). *P <0.05. All experiments were repeAmong the M1 and M2 macrophage markers, we selected
10 markers and confirmed in RAW264.7 cells using the
RT-PCR method. As a result, we found that phenotype
of RAW264.7 cells seem to be M1 type macrophages.
Therefore, we conducted a co-culture experiment using
RAW264.7 cells as a M1 type macrophage (Figure 6B
and Additional files 3 and 4). We confirmed this hy-
pothesis by co-culturing SL4-Cont and SL4-CXCL16
with RAW 264.7 cells and then a TNF-α neutralizing
antibody was added to detect differences in cell death.
Apoptosis of SL4-CXCL16 was significantly increased
by co-culture with RAW 264.7 cells (Figure 6B, middle
bar), and neutralization of TNF-α significantly inhibited
this response (Figure 6B, right bar). This observation con-
firmed that CXCL16 expression sensitized the metastatic
CRC cell line to apoptosis induced by TNF-α secreted by
macrophages. Treatment of mice with 2-chloroadenosine,
which is used for macrophage depletion [39], restored liver
metastasis (Figure 6C) and also significantly increased
tumor weight (Figure 6D). Collectively, these results sug-
gest that CXCL16 expression by SL4 cells induced the
accumulation of M1 macrophages, which then induced
apoptosis in SL4 cells by secreting TNF-α, thereby leading
to inhibition of metastasis.tic CRC cells. (A) Liver metastasis of SL4 cells. (B) Number of nodules
) Tumor weight of liver metastasis. Similar results were obtained from
ated at least three times.
Figure 6 Effect of 2-chloroadenosine on CXCL16-mediated inhibition of liver metastasis by SL4-CXCL16 cells. (A) M1 macrophage markers
and TNF-α were detected by RT-PCR. GAPDH was used as the normalization control. N, normal; T, tumor. (B) Cytotoxicity of macrophage-derived TNF-α
and recovery by TNF-α neutralizing antibody in SL4 cells. Cells (5 × 104 cells) were seeded in 24-well plates and a TNF-α neutralizing antibody added
(2.5 μg/ml). RAW 264.7 cells (5 × 104 cells) were seeded in migration chambers and co-cultured. Cells were removed from the chambers and
their viability was measured by WST-8 assay. *P <0.05, compared with control. #P <0.05, compared with RAW co-culture. (C and D) Restoration
of liver metastasis by CXCL16 expression in a macrophage depletion model. 2-Chloroadenosine was dissolved in saline and injected intraperitoneally
(50 μg/100 μl) 24 h before tumor inoculation. *P <0.05. All experiments were repeated at least three times.
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Chemokines have potential use in cancer gene therapy
due to their ability to attract immune cells. However, the
metastatic effect of tumor cell-derived CXCL16 on colo-
rectal liver metastasis has not been clarified. The forced
expression of CXCL16 in our SL4 subline affected the
expression of genes involved in the TNF and apoptosis
pathways (Table 1), which provided the first clue to the
role of CXCL16 as an intracellular signaling molecule.
IRF8, which was strongly upregulated in SL4-CXCL16
cells (Table 1), has been reported to sensitize Fas-mediated
apoptosis in soft tissue sarcoma cells and to modulate the
metastatic phenotype of CRC by regulating Fas expression
[37,38]. We confirmed increased IRF8 expression in SL4-
CXCL16 cells (Figure 3A) and that knockdown of CXCL16decreased IRF8 expression in these cells (Figure 3B and C).
Conversely, CXCL16 expression was decreased by knock-
down of IRF8 in SL4-CXCL16 cells (data not shown), indi-
cating mutual regulation of CXCL16 and IRF8 expression.
Knockdown of IRF8 expression also significantly de-
creased TNF-α-induced apoptosis in SL4-CXCL16 cells
(Figure 4B and C). The Bcl-2 family is regulated by IRF8
in soft tissue sarcoma cells and myeloid cells [40-42],
but we found no effect of IRF8 on the Bcl-2 family in
SL4 cells (data not shown). Instead, IRF8 appeared to regu-
late the caspase-3- and PARP-mediated apoptosis pathways
following TNF-α treatment (Figure 4). Based on these data,
we conclude that CXCL16 upregulates the expression
of IRF8, which in turn determines the sensitivity to
TNF-α-induced apoptosis. This result provides the first
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lular signaling molecule. Further studies are now
needed to determine how the constitutive expression
of CXCL16 mediates intracellular signaling.
Soluble CXCL16 is a chemoattractant that induces
directed migration of CXCR6-expressing cells [7,12,13].
Macrophages do not express CXCR6 and therefore are
not attracted by CXCL16. However, CXCL16 positively
regulates macrophage accumulation in injured muscle [43],
suggesting that an indirect mechanism exists for the at-
traction of macrophages by CXCL16. Our analysis of the
metastatic tumor tissues of SL4-CXCL16 cells indicated
the accumulation of NKT cells [44].
Suppression of liver metastasis by CXCL16 expression
was partially dampened in NKT cells-depleted mice (data
not shown) and infiltration of M1 macrophages was also
decreased in these mice (data not shown). NKT cell acti-
vation has also been reported following injection of α-
galactosylceramide, which induced the infiltration of M1
macrophages and production of TNF-α [45]. Therefore,
NKT cells attracted by CXCL16 may have induced M1
macrophage infiltration to the liver and thus indirectly
affected liver metastasis through TNF-α production; how-
ever, further studies are needed to elucidate the relation-
ship between NKT cells and macrophages.
M1 macrophages produce TNF-α, which has cytotoxic ac-
tivity against tumor cells [30]. We showed that co-cultured
M1 macrophage-like RAW 264.7 cells induced apoptosis in
SL4-CXCL16 cells (Figure 6B). Furthermore, liver metastasis
by SL4-CXCL16 cells was significantly increased in mice
treated with 2-chloroadenosine (Figure 6C and D) to deplete
macrophage numbers and depletion of macrophages also re-
duced TNF-α production (data not shown).
Conclusions
In conclusion, we have shown that tumor-derived CXCL16
is a key factor in colorectal liver metastasis. Overexpression
of CXCL16 sensitizes metastatic CRC cells to TNF-α-
induced apoptosis via IRF8. Moreover, CXCL16 also in-
directly induces the infiltration of M1 macrophages, which
induce tumor cell apoptosis by secreting TNF-α. CXCL16
may be an attractive candidate for gene therapy in colorec-
tal liver metastasis because of its effective dual approach
of not only accumulating TAMs, but also increasing can-
cer cell apoptosis. Although further studies are required to
obtain greater insight into the function of this molecule,
CXCL16 may have a vital role in the study of cancer
immunology and cancer biology.
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Additional file 1: Expression of membrane-bound CXCL16 on
SL4-CXCL16 cells SL4-CXCL16 cells were incubated with goat
anti-mouse CXCL16 mAb (R&D Systems, Minneapolis, MN, USA),or with control goat IgG (R&D Systems). FITC conjugated rabbit
anti-goat IgG (MP Bio Japan, Tokyo, Japan) was used as the second
antibody. FITC-labeled cells were then analyzed by flow cytometric
analysis using FACSCanto (BD Biosciences, San Diego, CA, USA). FACS
profiles by control goat IgG (open area) and anti-mouse CXCL16 mAb
(shaded area) are shown.
Additional file 2: Expression of CXCR6 on SL4-CXCL16 cells. SL4-CXCL16
cells were incubated with FITC conjugated rat anti-mouse CXCR6 mAb
(R&D Systems, Minneapolis, MN, USA), or with FITC conjugated control
rat IgG (R&D Systems). FACS profiles by control rat IgG (black line) and
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Additional file 3: mRNA levels of M1 and M2 macrophage markers in
RAW 264.7 cells. RT-PCR analysis was performed for identification of RAW
264.7 cells phenotype. Briefly, RAW 264.7 cells were seeded in 6-well
plates and incubated for 24 h without stimulation. Cells were harvested
using scraper and total RNA were extracted. GAPDH was used as the
normalization control. The primer sequences are shown in methods and
Additional file 4.
Additional file 4: Sequences of the RT-PCR primers.
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